<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577027</url>
  </required_header>
  <id_info>
    <org_study_id>FETV</org_study_id>
    <nct_id>NCT04577027</nct_id>
  </id_info>
  <brief_title>Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo</brief_title>
  <official_title>Safety And Efficacy Of Topical Prostaglandin F2α Analogs In Combination With Fractional CO2 Laser And 308 Excimer Light In Treatment Of Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitiligo is a chronic disease with an unpredictable clinical course, characterized by the&#xD;
      appearance of white macules and patches on the skin and mucous membranes due to the&#xD;
      disappearance of melanocytes in the affected area.&#xD;
&#xD;
      It affects approximately 0.5% - 2% of the population worldwide and may occur at any age.&#xD;
&#xD;
      Vitiligo is caused by a dynamic interplay between genetic and environmental risks that&#xD;
      initiates an autoimmune attack on melanocytes in the skin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of vitiligo has been a challenge for dermatologists. Recent reports have&#xD;
      highlighted darkening of iris, and eyelashes and periocular hyperpigmentation induced by&#xD;
      prostaglandin F2α analogues used for the treatment of glaucoma (as travoprost). Extrapolating&#xD;
      these findings in the treatment of vitiligo.&#xD;
&#xD;
      The beneficial effect of fractional CO2 laser on vitiligo is postulated to come from the&#xD;
      release of cytokines and growth factors that act as mitogens for melanogenesis . The&#xD;
      preceding laser also alters the skin barrier, which results in increased penetration of&#xD;
      topical drugs and ultraviolet (UV) radiation.&#xD;
&#xD;
      308 nm excimer laser is a monochromatic, target type treatment and allows the delivery of&#xD;
      higher fluences to the lesions and avoids damage to the surrounding normal skin resulting in&#xD;
      a faster and more effective pigmentation with minimal side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>no masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>clinical improvement through VASI score</measure>
    <time_frame>9 months</time_frame>
    <description>VASI score will be calculated for each patient at start, every 4 weeks and 6 months after the last session.&#xD;
VASI = ∑ all treated sites [number of hand units] X [% residual depigmentation].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients satisfaction</measure>
    <time_frame>9 months</time_frame>
    <description>according to the following scale:&#xD;
dissatisfied&#xD;
neutral&#xD;
somewhat satisfied&#xD;
moderately satisfied&#xD;
very satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent of repigmentation</measure>
    <time_frame>9 months</time_frame>
    <description>The percent of repigmentation will be calculated every 4 weeks of treatment and 6 months after the last session by a scoring system .&#xD;
&lt; 25% repigmentation (poor response). 25-50% repigmentation (fair response). 50-75% repigmentation (good response). &gt; 75% repigmentation (excellent response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological evaluation</measure>
    <time_frame>9 months</time_frame>
    <description>Skin biopsy will be taken from the treated lesions after treatment, Hematoxylin and eosin-stained slides will be examined microscopically to evaluate the epidermal and dermal pathological changes: (1) evaluation of dermal perivascular inflammatory infiltrate density; (2) signs of pigmentation in the form of residual melanin in epidermis or dermal melanophages .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vitiligo</condition>
  <condition>Excimer Laser</condition>
  <condition>Fractional CO2 Laser</condition>
  <arm_group>
    <arm_group_label>vitiligo patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thirty Patients complaining of generalized non segmental vitiligo will be recruited in this study. They will be chosen from the attendants of the out-patient clinics of Dermatology, Assiut university hospital. six patches will be selected in each patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical travoprost 0.004% solution</intervention_name>
    <description>30 Patches treated with Topical Travoprost 0.004% solution: Topical travoprost 0.004% solution once daily (1 drop for each 2.5 x 2.5 cm2) for 3 months.</description>
    <arm_group_label>vitiligo patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractional CO2 laser</intervention_name>
    <description>30 Patches treated with Fractional CO2 laser: Fractional CO2 laser sessions twice monthly for 3 months, parameters settings as follows: Energy\ dot 100mj, pulse duration 5ms, density level 17, pattern: array, depth level 1, 2 passes used</description>
    <arm_group_label>vitiligo patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Excimer laser</intervention_name>
    <description>30 Patches treated with Excimer laser: Excimer laser sessions will be repeated twice weekly on the selected patch only, The starting dose will be 200 mj /cm2, an increase of 100 mJ/cm2 in the following session if no erythema appears, an increase of 50 mJ/cm2 every session till the appearance of erythema that lasts 24 hours or more.</description>
    <arm_group_label>vitiligo patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Combination therapy</intervention_name>
    <description>30 Patches treated with Combination therapy: Fractional CO2 laser twice per month followed by application of topical travoprost 0,004% daily and excimer laser twice weekly .</description>
    <arm_group_label>vitiligo patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Excimer laser and travoprost</intervention_name>
    <description>30 Patches treated with Excimer laser twice weekly and topical travoprost once daily for 3 months</description>
    <arm_group_label>vitiligo patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fractional CO2 laser and topical travoprost</intervention_name>
    <description>30 Patches treated with fractional CO2 laser twice monthly and topical travoprost once daily for 3 months</description>
    <arm_group_label>vitiligo patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients older than 12 years.&#xD;
&#xD;
          2. Patients with generalized non-segmental vitiligo.&#xD;
&#xD;
          3. No previous treatment for vitiligo in the last 1 month.&#xD;
&#xD;
          4. Patients who were unresponsive to medical treatment or photo therapy for at least 3&#xD;
             months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with sensitivity to travoprost.&#xD;
&#xD;
          2. Patients with photosensitivity.&#xD;
&#xD;
          3. Patients with history or active skin cancer.&#xD;
&#xD;
          4. No other dermatological or systemic diseases.&#xD;
&#xD;
          5. Active infections .&#xD;
&#xD;
          6. Pregnant or lactating females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hatem Zidan, Prof.DR</last_name>
    <phone>01003420217</phone>
    <email>hzma03@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yasmin Tawfik, DR</last_name>
  </overall_contact_backup>
  <reference>
    <citation>Fa Y, Lin Y, Chi XJ, Shi WH, Wang JL, Guo X, Geng JH, Liu HX, Zhang FR. Treatment of vitiligo with 308-nm excimer laser: our experience from a 2-year follow-up of 979 Chinese patients. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):337-340. doi: 10.1111/jdv.13917. Epub 2016 Sep 19.</citation>
    <PMID>27538097</PMID>
  </reference>
  <reference>
    <citation>Kim HJ, Hong ES, Cho SH, Lee JD, Kim HS. Fractional Carbon Dioxide Laser as an &quot;Add-on&quot; Treatment for Vitiligo: A Meta-analysis with Systematic Review. Acta Derm Venereol. 2018 Feb 7;98(2):180-184. doi: 10.2340/00015555-2836. Review.</citation>
    <PMID>29110015</PMID>
  </reference>
  <reference>
    <citation>Khattab FM, Abdelbary E, Fawzi M. Evaluation of combined excimer laser and platelet-rich plasma for the treatment of nonsegmental vitiligo: A prospective comparative study. J Cosmet Dermatol. 2020 Apr;19(4):869-877. doi: 10.1111/jocd.13103. Epub 2019 Sep 21.</citation>
    <PMID>31541597</PMID>
  </reference>
  <reference>
    <citation>Wong L, Vasconez HC. Patient satisfaction after Nd:YAG laser-assisted lipolysis. Ann Plast Surg. 2011 May;66(5):561-3. doi: 10.1097/SAP.0b013e31820b3d1e.</citation>
    <PMID>21451378</PMID>
  </reference>
  <reference>
    <citation>Doghaim NN, Gheida SF, El-Tatawy RA, Mohammed Ali DA. Combination of fractional carbon dioxide laser with narrow band ultraviolet B to induce repigmentation in stable vitiligo: A comparative study. J Cosmet Dermatol. 2019 Feb;18(1):142-149. doi: 10.1111/jocd.12553. Epub 2018 Apr 30.</citation>
    <PMID>29707867</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>GAbdelsamea</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

